Reshape Lifesciences (Reshape Lifesciences) FCF Margin % : -106.58% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Reshape Lifesciences FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Reshape Lifesciences's Free Cash Flow for the three months ended in Mar. 2024 was $-2.07 Mil. Reshape Lifesciences's Revenue for the three months ended in Mar. 2024 was $1.94 Mil. Therefore, Reshape Lifesciences's FCF Margin % for the quarter that ended in Mar. 2024 was -106.58%.

As of today, Reshape Lifesciences's current FCF Yield % is -317.62%.

The historical rank and industry rank for Reshape Lifesciences's FCF Margin % or its related term are showing as below:

RSLS' s FCF Margin % Range Over the Past 10 Years
Min: -7755.14 Med: -196.02 Max: -79.12
Current: -168.05

During the past 13 years, the highest FCF Margin % of Reshape Lifesciences was -79.12%. The lowest was -7755.14%. And the median was -196.02%.

RSLS's FCF Margin % is ranked worse than
81.25% of 832 companies
in the Medical Devices & Instruments industry
Industry Median: -7.45 vs RSLS: -168.05

Reshape Lifesciences FCF Margin % Historical Data

The historical data trend for Reshape Lifesciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reshape Lifesciences FCF Margin % Chart

Reshape Lifesciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-94.20

-79.12

-115.64

-196.02

-195.93

Reshape Lifesciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-221.60	-297.16	-129.00	-123.97	-106.58

Competitive Comparison of Reshape Lifesciences's FCF Margin %

For the Medical Devices subindustry, Reshape Lifesciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Reshape Lifesciences's FCF Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Reshape Lifesciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Reshape Lifesciences's FCF Margin % falls into.

Reshape Lifesciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Reshape Lifesciences's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-17.003	/	8.678
	=	-195.93 %

Reshape Lifesciences's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-2.072	/	1.944
	=	-106.58 %

Reshape Lifesciences FCF Margin % Related Terms

Thank you for viewing the detailed overview of Reshape Lifesciences's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Reshape Lifesciences (Reshape Lifesciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Reshape Lifesciences Inc (NAS:RSLS) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1001 Calle Amanecer, San Clemente, CA, USA, 92673

Website

https://www.reshapelifesciences.com

Reshape Lifesciences Inc is a developer of minimally invasive medical devices to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.

Executives

Thomas Stankovich	officer: Chief Financial Officer	1001 CALLE AMANECER, SAN CLEMENTE CA 92673
Paul F. Hickey	director, officer: President and CEO	2800 PATTON ROAD, ST. PAUL MN 55113
Barton P. Bandy	director	1001 CALLE AMANECER, SAN CLEMENTE CA 92673
Mcdougal Lori Courtney	director	2800 PATTON ROAD, ST. PAUL MN 55113
Arda Phd Minocherhomjee	director	C/O CHICAGO GROWTH PARTNERS, 303 W MADISON ST., SUITE 2500, CHICAGO IL 60606
Dan W Gladney	director	2800 PATTON ROAD, ST. PAUL MN 55113
Steven Boyd	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Gary Blackford	director	7700 FRANCE AVENUE SOUTH, EDINA MN 55435
Robert J Macdonald	officer: Chief Retail Officer	C/O OBALON THERAPEUTICS INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Daina Schmidt	officer: Vice President of Marketing	C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, SAN DIEGO CA 92008
Gilbert H Kliman	10 percent owner	C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Arnold L Oronsky	10 percent owner	C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Khaled Nasr	10 percent owner	467 FIRST STREET, SUITE 201, LOS ALTOS X1 94022
Interwest Partners X Lp	10 percent owner	C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022